Etonogestrel

Revision as of 02:26, 9 August 2012 by WikiBot (talk | contribs) (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +))
Jump to navigation Jump to search


Etonogestrel
Clinical data
Routes of
administration
Subdermal as slow-release implant
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
MetabolismHepatic (P450 3A4)
Elimination half-life25 hours
ExcretionUrinary (majority) and fecal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H28O2
Molar mass324.457 g/mol

WikiDoc Resources for Etonogestrel

Articles

Most recent articles on Etonogestrel

Most cited articles on Etonogestrel

Review articles on Etonogestrel

Articles on Etonogestrel in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Etonogestrel

Images of Etonogestrel

Photos of Etonogestrel

Podcasts & MP3s on Etonogestrel

Videos on Etonogestrel

Evidence Based Medicine

Cochrane Collaboration on Etonogestrel

Bandolier on Etonogestrel

TRIP on Etonogestrel

Clinical Trials

Ongoing Trials on Etonogestrel at Clinical Trials.gov

Trial results on Etonogestrel

Clinical Trials on Etonogestrel at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Etonogestrel

NICE Guidance on Etonogestrel

NHS PRODIGY Guidance

FDA on Etonogestrel

CDC on Etonogestrel

Books

Books on Etonogestrel

News

Etonogestrel in the news

Be alerted to news on Etonogestrel

News trends on Etonogestrel

Commentary

Blogs on Etonogestrel

Definitions

Definitions of Etonogestrel

Patient Resources / Community

Patient resources on Etonogestrel

Discussion groups on Etonogestrel

Patient Handouts on Etonogestrel

Directions to Hospitals Treating Etonogestrel

Risk calculators and risk factors for Etonogestrel

Healthcare Provider Resources

Symptoms of Etonogestrel

Causes & Risk Factors for Etonogestrel

Diagnostic studies for Etonogestrel

Treatment of Etonogestrel

Continuing Medical Education (CME)

CME Programs on Etonogestrel

International

Etonogestrel en Espanol

Etonogestrel en Francais

Business

Etonogestrel in the Marketplace

Patents on Etonogestrel

Experimental / Informatics

List of terms related to Etonogestrel

Etonogestrel is a molecule used in hormonal contraceptives, most notably the subdermal implant Implanon.

Etonogestrel, the specific progestin used in NuvaRing, is the active metabolite of the inactive prodrug desogestrel, one of two third-generation progestins found in some epidemiological studies of combined oral contraceptive pills to be associated with a higher risk of venous thrombosis than combined oral contraceptive pills containing certain second-generation progestins. Because hormones are released continuously from NuvaRing, peak and total estrogen and progestin doses are significantly lower than with combined oral contraceptives, although it is not known whether this lowers the risk of blood clots.

See also

Template:Sex hormones

Template:WikiDoc Sources